Ambroxol, a beta-glucocerebrosidase 2 (GBA2) inhibitor originally indicated as a generic expectorant and mucolytic drug to treat respiratory tract infectious disorders (Nobata et al., 2006), has been recently found to be a potential drug candidate for ALS treatment. The gene discussed is GBA2; the disease is amyotrophic lateral sclerosis.